Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Renal Insufficiency × melflufen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 5 Renal Insufficiency 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 4 pomalidomide 2 Azacitidine 2 vinflunine 1 trifluridine tipiracil drug combination 1 trebananib 1 safinamide 1 sacubitril and valsartan sodium hydrate drug combination 1 rubitecan 1 ripretinib 1 regorafenib 1 pevonedistat 1 pembrolizumab 1 mirabegron 1 melflufen 1 gallium 68 PSMA-11 1 copanlisib 1 carfilzomib 1 belinostat 1 belantamab mafodotin 1 Topotecan 1 Tablets 1 Sitagliptin Phosphate 1 Pluvicto 1 Paclitaxel 1 Lenalidomide 1 L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1 Gemcitabine 1 Duration of Therapy 1 Cilengitide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03639610 2023-03-10

BRIDGE

Oncopeptides AB

Phase 2 Terminated

35 enrolled 33 charts

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon ⚡